Literature DB >> 26627192

In Vivo Gene-Silencing in Fibrotic Liver by siRNA-Loaded Cationic Nanohydrogel Particles.

Leonard Kaps1, Lutz Nuhn2,3, Misbah Aslam1, Alexander Brose1, Friedrich Foerster1,4, Sebastian Rosigkeit1, Patricia Renz5, Rosario Heck1, Yong Ook Kim1, Ingo Lieberwirth5, Detlef Schuppan1,6, Rudolf Zentel2.   

Abstract

Cationic nanohydrogel particles loaded with anti-Col1α1 siRNA suppress collagen synthesis and deposition in fibrotic mice: Systemically administered 40 nm sized nanogel particles accumulate in collagen-expressing cells in the liver. Their siRNA payload induces a sequence specific in vivo gene knockdown affording an efficient antifibrotic effect in mice with liver fibrosis.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cationic nanohydrogels; in vivo gene knockdown; liver fibrosis; nanogels; siRNA delivery

Mesh：

Substances：

Year:  2015        PMID： 26627192     DOI： 10.1002/adhm.201500826

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN： 2192-2640            Impact factor:   9.933


  11 in total

1.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 2.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

3.  Injectable nanofibrous spongy microspheres for NR4A1 plasmid DNA transfection to reverse fibrotic degeneration and support disc regeneration.

Authors:  Ganjun Feng; Zhanpeng Zhang; Ming Dang; Xiaojin Zhang; Yasmine Doleyres; Yueming Song; Di Chen; Peter X Ma
Journal:  Biomaterials       Date:  2017-03-24       Impact factor: 12.479

Review 4.  Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.

Authors:  Sudeep Tanwar; Freya Rhodes; Ankur Srivastava; Paul M Trembling; William M Rosenberg
Journal:  World J Gastroenterol       Date:  2020-01-14       Impact factor: 5.742

5.  In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by α-Mannosyl-Functionalized Cationic Nanohydrogel Particles.

Authors:  Leonard Kaps; Nadine Leber; Adrian Klefenz; Niklas Choteschovsky; Rudolf Zentel; Lutz Nuhn; Detlef Schuppan
Journal:  Cells       Date:  2020-08-15       Impact factor: 6.600

Review 6.  Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology.

Authors:  Ernesto Bockamp; Sebastian Rosigkeit; Dominik Siegl; Detlef Schuppan
Journal:  Cells       Date:  2020-09-15       Impact factor: 6.600

7.  pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages.

Authors:  Leonard Kaps; Anne Huppertsberg; Niklas Choteschovsky; Adrian Klefenz; Feyza Durak; Babara Schrörs; Mustafa Diken; Emma Eichler; Sebastian Rosigkeit; Sascha Schmitt; Christian Leps; Alicia Schulze; Friedrich Foerster; Ernesto Bockamp; Bruno G De Geest; Kaloian Koynov; Hans-Joachim Räder; Stefan Tenzer; Federico Marini; Detlef Schuppan; Lutz Nuhn
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-15       Impact factor: 12.779

Review 8.  The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.

Authors:  Maurice Michel; Leonard Kaps; Annett Maderer; Peter R Galle; Markus Moehler
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 9.  Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers.

Authors:  Leonard Kaps; Detlef Schuppan
Journal:  Cells       Date:  2020-09-03       Impact factor: 6.600

Review 10.  Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy.

Authors:  Maximiliano L Cacicedo; Carolina Medina-Montano; Leonard Kaps; Cinja Kappel; Stephan Gehring; Matthias Bros
Journal:  Cells       Date:  2020-08-28       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.